Search

Howard S Scher

from Roswell, GA
Age ~61
Get Report
Also known as:
Howard Scott Scher, Howard S Schert, Howard S Stacey, Scott Scher, Stacey Scher, Counsel Group Inc Regulatory
Phone and address:
4060 Rockingham Dr, Roswell, GA 30075
(770) 992-7779
Connected to:
Anshel Scher, 62Brenda I Scher, 80Chelsea L Scher, 33Elka Scher, 34Ephraim Scher, 34Ethel M Scher, 105Grace S Scher, 75Janie W Scher, 75Liza G Scher, 68Moishe Scher, 62

Howard Scher Phones & Addresses

  • 4060 Rockingham Dr, Roswell, GA 30075 (770) 992-7779 (212) 865-4631
  • 4060 Rockingham Dr APT 1, Roswell, GA 30075
  • 295 W Crossville Rd #5 # 530, Roswell, GA 30075 (770) 992-7779
  • 1 Home Campus, Des Moines, IA 50328
  • 795 Hammond Dr, Atlanta, GA 30328 (404) 255-1741 (404) 303-7480
  • 795 Hammond Dr NE #501, Atlanta, GA 30328 (770) 992-7779
  • Alpharetta, GA
  • 70 W 95Th St #5F, New York, NY 10025 (770) 992-7779
  • 640 W 153Rd St #C, New York, NY 10031
  • Marietta, GA
  • Redan, GA
  • 4060 Rockingham Dr, Roswell, GA 30075 (678) 480-7806

Work

Company: Sidney Kimmel Center Prostate/URO Address: 353 E 68Th St, New York, NY 10065 Phones: (646) 422-4317

Education

School / High School: New York University School Of Medicine 1976

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 1979

Specialities

Oncology • Medical Oncology

Professional Records

Medicine Doctors

Howard Scher Photo 1

Dr. Howard Scher, New York NY - MD (Doctor of Medicine)

View page
Specialties:
Oncology
Medical Oncology
Address:
1275 York Ave, New York, NY 10065
(800) 525-2225 (Phone)

Sidney Kimmel Center Prostate/URO
353 E 68Th St, New York, NY 10065
(646) 422-4317 (Phone)
Certifications:
Internal Medicine, 1979
Medical Oncology, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1275 York Ave, New York, NY 10065

Sidney Kimmel Center Prostate/URO
353 E 68Th St, New York, NY 10065

Memorial Sloan - Kettering Cancer Center
1275 York Avenue, New York, NY 10065
Education:
Medical School
New York University School Of Medicine
Graduated: 1976
Medical School
Bellevue Hosp Ctr-Nyu Sch Med
Graduated: 1976
Medical School
Sloan-Kettering Cancer Ctr
Graduated: 1976
Howard Scher Photo 2

Howard I. Scher

View page
Specialties:
Urology, Medical Oncology
Work:
Memorial Sloan Kettering Cancer Center Urology
353 E 68 St, New York, NY 10065
(646) 422-4329 (phone), (212) 988-0759 (fax)
Education:
Medical School
New York University School of Medicine
Graduated: 1976
Procedures:
Chemotherapy
Conditions:
Prostate Cancer
Acute Renal Failure
Anemia
Anxiety Dissociative and Somatoform Disorders
Bacterial Pneumonia
Languages:
English
Description:
Dr. Scher graduated from the New York University School of Medicine in 1976. He works in New York, NY and specializes in Urology and Medical Oncology. Dr. Scher is affiliated with Memorial Sloan Kettering Cancer Center.
Howard Scher Photo 3

Howard I Scher, New York NY

View page
Specialties:
Internal Medicine
Medical Oncology
Hematology & Oncology
General Practice
Work:
Memorial Sloan-Kettering
1275 York Ave, New York, NY 10065
Education:
New York University (1976)

Lawyers & Attorneys

Howard Scher Photo 4

Howard D. Scher, New York NY - Lawyer

View page
Address:
Buchanan Ingersoll & Rooney PC
1290 Avenue Of The Americas 30Th Floor, New York, NY
(212) 440-4495 (Office), (215) 665-3920 (Office), (215) 990-9989 (Mobile)
Buchanan Ingersoll & Rooney PC
50 South 16Th Street Suite 3200, Philadelphia, PA 19102
(215) 655-3920 (Office), (215) 990-9989 (Mobile), (212) 440-4495 (Office)
Licenses:
New York - Currently registered 2008
Pennsylvania - Active 1971
Education:
Rutgers University School of Law
Degree - JD - Juris Doctor - Law
Graduated - 1971
Brandeis University
Degree - BA - Bachelor of Arts
Graduated - 1967
Specialties:
Litigation - 20%
Antitrust / Trade Law - 20%
Appeals - 20%
Contracts / Agreements - 20%
Communications / Media - 20%
Associations:
American Bar Association - Member
American College of Trial Lawyers - Member
International Academy of Trial Lawyers - Chairman
Pennsylvania Bar Association - Member
Philadelphia Bar Association - Chairman
Temple American Inn of Court - Member
Description:
Please see http://www.buchananingersoll.com/professionals.php?PeopleID=446 [http://www.buchananingersoll.com/professionals.php?PeopleID=446]for further information.

Business Records

Name / Title
Company / Classification
Phones & Addresses
Howard S. Scher
Principal
Recruit Screen
Business Services · Management Consulting Services
802 Abbey Ct, Alpharetta, GA 30004
Howard Isador Scher
Howard Scher MD
Internist
1275 York Ave, New York, NY 10065
(646) 227-3813
Howard I. Scher
Urology
Memorial Sloan-Kettering Cancer Center
Medical Doctor's Office · Nonclassifiable Establishments
353 E 68 St, New York, NY 10065
Howard I. Scher
Urology
Memorial Sloan- Kettering Cancer Center
Specialty Hospital
415 E 68 St, New York, NY 10065
(646) 888-2300

Publications

Us Patents

Markers For Prostate Cancer

View page
US Patent:
6972170, Dec 6, 2005
Filed:
Jun 10, 1999
Appl. No.:
09/329917
Inventors:
Carlos Cordon-Cardo - New York NY, US
Howard I. Scher - Tenafly NJ, US
Andrew Koff - Westbury NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
C12Q001/68
G01N033/53
C12P019/34
US Classification:
435 6, 435 71, 435 911, 435 912
Abstract:
This invention provides a method for determining the aggressiveness of a prostate carcinoma comprising: (a) obtaining a sample of the prostate carcinoma; and (b) detecting the presence of p27 protein in the prostate carcinoma, the absence of p27 indicating that the prostate carcinoma is aggressive. This invention also provides a method for diagnosing a beign prostate hyperplasia comprising: (a) obtaining an appropriate sample of the hyperplasia; and (b) detecting the presence of the p27 RNA, a decrease of the p27 RNA indicating that the hyperplasia is beign. This invention provides various uses of p27 in prostate cancer. Finally, this invention also provides different marker for prostate cancer.

Markers For Prostate Cancer

View page
US Patent:
20040053247, Mar 18, 2004
Filed:
Nov 5, 2002
Appl. No.:
10/288609
Inventors:
Carlos Cordon-Cardo - New York NY, US
Howard Scher - Tenafly NJ, US
Andrew Koff - Westbury NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research
International Classification:
C12Q001/68
G01N033/574
US Classification:
435/006000, 435/007230
Abstract:
This invention provides a method for determining the aggressiveness of a prostate carcinoma comprising: (a) obtaining a sample of the prostate carcinoma; and (b) detecting the presence of p27 protein in the prostate carcinoma, the absence of p27 indicating that the prostate carcinoma is aggressive. This invention also provides a method for diagnosing a beign prostate hyperplasia comprising: (a) obtaining an appropriate sample of the hyperplasia; and (b) detecting the presence of the p27 RNA, a decrease of the p27 RNA indicating that the hyperplasia is beign. This invention provides various uses of p27 in prostate cancer. Finally, this invention also provides different marker for prostate cancer.

Synthesis Of Glycoconjugates Of The Globo-H Epitope And Uses Thereof

View page
US Patent:
6544952, Apr 8, 2003
Filed:
Feb 2, 1998
Appl. No.:
09/017611
Inventors:
Samuel J. Danishefsky - Englewood NJ
Philip O. Livingston - New York NY
In Jong Kim - New York NY
Howard Scher - Tenafly NJ
Susan Slovin - New York NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A01N11304
US Classification:
514 23, 514 42, 514 54, 514 62, 4241841, 4242771
Abstract:
The present invention provides a method of synthesizing a compound having the structure: as well as other related glycoconjugates useful as vaccines for inducing antibodies to epithelial cancer cells in an adjuvant therapy therefore, and in a method for preventing recurrence of epithelial cancer. The present invention also provides a vaccine comprising an amount of the compound described above effective to prevent the recurrence of cancer in a subject.

Methods Of Cancer Treatment Via Regulated Ferroptosis

View page
US Patent:
20200383943, Dec 10, 2020
Filed:
Dec 4, 2018
Appl. No.:
16/769501
Inventors:
- New York NY, US
- Ithaca NY, US
Howard Scher - Tenafly NJ, US
Ulrich Wiesner - Ithaca NY, US
Brian Madajewski - New York NY, US
International Classification:
A61K 31/198
A61P 35/00
A61K 47/69
Abstract:
The present disclosure describes methods of treatment (e.g., combination treatment) by ferroptotic induction, as well as compositions and dosing regimens that are part of such methods. Surprisingly, it is presently found that delaying administration of a ferroptosis-inducing agent until after starting hormone therapy results in enhanced ferroptotic induction in a subject. Thus, in certain embodiments, combination therapies are presented herein that include multiple administration steps whereby a ferroptosis-inducing agent is administered some time after hormone therapy has begun.

Methods Of Treatment Using Ultrasmall Nanoparticles To Induce Cell Death Of Nutrient-Deprived Cancer Cells Via Ferroptosis

View page
US Patent:
20200316219, Oct 8, 2020
Filed:
Jun 16, 2020
Appl. No.:
16/902577
Inventors:
- New York NY, US
- Ithaca NY, US
Michael Overholtzer - Glen Ridge NJ, US
Howard Scher - Tenafly NJ, US
Kai Ma - Ithaca NY, US
International Classification:
A61K 47/69
A61K 47/60
A61K 38/22
Abstract:
Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

Inhibitor-Functionalized Ultrasmall Nanoparticles And Methods Thereof

View page
US Patent:
20190282712, Sep 19, 2019
Filed:
Nov 29, 2017
Appl. No.:
16/463865
Inventors:
- New York NY, US
- Ithaca NY, US
- Columbia MO, US
Wolfgang Weber - Larchmont NY, US
Karim Touijer - New York NY, US
Howard Scher - Tenafly NJ, US
Kai Ma - Ithaca NY, US
Ulrich Wiesner - Ithaca NY, US
International Classification:
A61K 49/00
A61K 51/08
A61K 51/12
C07K 7/02
Abstract:
Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a polymer, a protein). Such conjugates exhibit distinct properties over the free, unbound inhibitor/chelator construct.

Methods Of Treatment Using Ultrasmall Nanoparticles To Induce Cell Death Of Nutrient-Deprived Cancer Cells Via Ferroptosis

View page
US Patent:
20180169264, Jun 21, 2018
Filed:
May 26, 2016
Appl. No.:
15/573855
Inventors:
- New York NY, US
- Ithaca NY, US
Michael Overholtzer - New York NY, US
Howard Scher - Tenafly NJ, US
Kai Ma - Ithaca NY, US
International Classification:
A61K 47/69
A61K 47/60
A61K 38/22
Abstract:
Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

Genes Associated With Dasatinib Sensitivity

View page
US Patent:
20150240314, Aug 27, 2015
Filed:
Sep 16, 2013
Appl. No.:
14/428248
Inventors:
- New York NY, US
Howard I. Scher - Tenafly NJ, US
Martin Fleisher - Glen Cove NY, US
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER - New York NY
International Classification:
C12Q 1/68
G06F 19/00
G06F 19/20
Abstract:
The invention relates to a method for the Cell Type specific labeling with Amino acid Precursors (CTAP). In particular, the disclosed method permits the incorporation of stable isotope-labeled amino acids into the proteome of a vertebrate cell that has been engineered to express an exogenous enzyme that enables the cell to produce an essential amino acid from its amino acid substrate. The method employs stable isotope-labeled amino acid substrate/precursors from which essential amino acids bearing the label are generated. The labeled amino acids generated by the transgenic cell not only supports growth but specifically labels proteins of the transgenic cell. Furthermore, the use of different populations of cells expressing different exogenous amino acid-producing enzymes permits differential labeling of the proteomes of the individual cell populations in multicellular environments.

Isbn (Books And Publications)

Principles and Practice of Genitourinary Oncology

View page
Author

Howard I. Scher

ISBN #

0397514581

Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Proceedings of an International Workshop Held in San Francisco, May 19-20, 1989

View page
Author

Howard I. Scher

ISBN #

0471568171

Control profile
Howard S Scher from Roswell, GA, age ~61 Get Report